Study S000997

A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05794581
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 32
Start: 2023-03-21
Primary completion: 2024-03-06
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Type 1 Diabetes
Interventions: DRUG:CT-868; DRUG:Placebo; DRUG:Victoza
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To assess area under the curve (AUC) in glucose metabolism during MMTT [Baseline up to 4 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.